Amber-UI: A closed-loop bioelectronic system for urinary incontinence

Amber-UI：治疗尿失禁的闭环生物电子系统

• 批准号: 95110
• 金额: $ 141.11万
• 依托单位: AMBER THERAPEUTICS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=95110
• 关键词: Amber; UI; closed; loop; bioelectronic

Urinary incontinence (UI) is a common condition that can severely impact physical, mental and financial wellbeing. Though it is thought at least 8.5% of the global population suffer from UI, many do not admit it, with fewer than half of adults with severe UI seeking help from healthcare providers; one study found that men would rather admit to sexual impotence than symptoms of incontinence.Amber-UI will be a highly innovative implantable bioelectronic neuroprosthesis intended to provide synthetic continence reflexes in patients with UI who have not responded to simple treatments like lifestyle changes, pelvic floor exercises, medication, bladder injections, etc.Where current options for these patients consist of high-risk, variably successful surgery or dated on-size-fits-all electrical stimulation therapies that mostly only reduce rather than cure symptoms, Amber-UI will bring intelligent adaptive stimulation. It will respond to the individual patient's physiology and measurable biomarkers of both 'urge' (the sudden need to urinate) and 'stress' events (coughing, sneezing, lifting, etc). In effect, Amber-UI will restore the normal mechanisms of continence in a large group of UI patients so that they remain dry all the time---transforming these patients' lives.Conducting experimental medicine in first-time-in-human studies, this project will refine Amber-UI's minimally-invasive surgical technique so that it requires a similar surgeon skill/time commitment as current electrical stimulation therapy surgeries, and it will explore and optimise Amber-UI sensing and stimulation to ultimately provide patients with synthetic reflex control of continence.

尿失禁是一种常见的疾病，会严重影响身体、精神和经济健康。尽管据认为全球至少有8.5%的人口患有尿失尿，但许多人不承认这一点，只有不到一半的严重尿失尿的成年人向医疗保健提供者寻求帮助；一项研究发现，男性宁愿承认自己性无能，也不愿承认自己有尿失禁的症状。Amber-UI将是一种高度创新的植入式生物电子神经假体，旨在为对生活方式改变、盆底运动、药物治疗、膀胱注射等简单治疗无效的尿失禁患者提供合成失禁反射。目前，这些患者的选择包括高风险、不太成功的手术或过时的通用电刺激疗法，这些疗法大多只能减轻而不能治愈症状。琥珀ui将带来智能自适应刺激。它将对个体患者的生理和可测量的生物标志物做出反应，包括“冲动”（突然需要小便）和“压力”事件（咳嗽、打喷嚏、抬起等）。实际上，Amber-UI将恢复一大群尿失禁患者的正常失禁机制，使他们始终保持干燥，从而改变这些患者的生活。该项目将首次在人体中进行实验医学研究，将完善Amber-UI的微创手术技术，使其需要与当前电刺激治疗手术相似的外科医生技能/时间承诺，并将探索和优化Amber-UI的传感和刺激，最终为患者提供自制的合成反射控制。